Monday, November 23, 2009, 9:01pm EST - Canadian Markets are closed.
To create a watchlist or portfolio of shares, Sign-in or Register

Urologix, Inc. (ULGX)

 At 15:59 EST: 0.94 USD  Down 0.04 (4.08%)  
MORE ON ULGX
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Urologix, Inc. (NCM:ULGX) Delayed quote dataEdit
Last Trade: 0.94 USD
Trade Time: 3:59PM EST
Change: Down 0.04 (4.08%)
Prev Close: 0.98
Open: 0.99
Bid: 0.81 x 200
Ask: N/A
1y Target Est: 2.00
Day's Range: 0.90 - 1.01
52wk Range: 0.21 - 1.31
Volume: 15,365
Avg Vol (3m): 16,963.1
Market Cap: 13.62M
P/E (ttm): N/A
EPS (ttm): -0.27
Div & Yield: N/A (N/A%)
Urologix, Inc. (ULGX)
1d  5d  3m  6m  1y  2y  5y  max 
 Add ULGX to Portfolio   Download Data

HEADLINES
• UROLOGIX INC Financials
EDGAR Online Financials (Wed, Nov 18)
• UROLOGIX INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Thu, Nov 12)
• UROLOGIX INC Files SEC form 8-K, Regulation FD Disclosure
EDGAR Online (Tue, Nov 10)
• UROLOGIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online (Wed, Oct 28)
• Urologix Inc. F1Q10 (Qtr End 30/09/09) Earnings Call Transcript
at Seeking Alpha (Tue, Oct 27)
• Urologix, Inc. Earnings Call scheduled for 5:00 pm ET today
CCBN (Tue, Oct 27)
• Urologix Reports Revenue Growth over Prior Periods in First Quarter of Fiscal Year 2010
Business Wire (Tue, Oct 27)
• Q1 2010 Urologix, Inc. Earnings Release - After Market Close
CCBN (Tue, Oct 27)
• Urologix to Host Its Fiscal 2010 First Quarter Conference Call
Business Wire (Wed, Oct 21)
• UROLOGIX INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tran
EDGAR Online (Fri, Oct 2)
More Headlines for ULGX...
ANALYST
EPS Est (next year) (Jun-10) : -0.20
EPS Est (in 2 years) (Jun-11) : N/A
Avg Rec (current)*: 3.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Urologix, Inc. operates as a medical device company that engages in developing, manufacturing, and marketing non-surgical therapies to treat benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices